Floatz logo

Casodex

Gastrointestinal Complications

University College, LondonPhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Gastrointestinal Complications cohort.

Asset / SponsorPhaseRating
Empagliflozin
Yonsei University
Phase 4BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Cedars-Sinai Medical Center
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Cedars-Sinai Medical Center
Phase 4BB

View all 44 →

Same molecule, other indications

Casodex is also rated in:

prostate adenocarcinomaDormant
BB
Indicative ·
69 / 100
View asset →
triple-negative breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →